Kornitzer Capital Management’s Protara Therapeutics TARA Stock Holding History

Kornitzer Capital Management’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-283	Closed	-$21K	–	482
2017 Q4	$21K	Sell	283 -342	-55%	-$27.4K	﹤0.01%	472
2017 Q3	$50K	Hold	625	–	–	﹤0.01%	460
2017 Q2	$38K	Buy	625 +140	+29%	+$7.84K	﹤0.01%	469
2017 Q1	$34K	Buy	485 +185	+62%	+$13.8K	﹤0.01%	462
2016 Q4	$23K	Hold	300	–	–	﹤0.01%	467
2016 Q3	$112K	Hold	300	–	–	﹤0.01%	449
2016 Q2	$96K	Hold	300	–	–	﹤0.01%	450
2016 Q1	$93K	Hold	300	–	–	﹤0.01%	444
2015 Q4	$186K	Hold	300	–	–	﹤0.01%	443
2015 Q3	$167K	Sell	300 -75	-20%	-$46.4K	﹤0.01%	431
2015 Q2	$268K	Hold	375	–	–	﹤0.01%	432
2015 Q1	$174K	Hold	375	–	–	﹤0.01%	434
2014 Q4	$156K	Buy	+375	New	+$151K	﹤0.01%	419

Other funds holding TARA

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kornitzer Capital Management's TARA Position: Q1 2018 in Review

Kornitzer Capital Management sold out of Protara Therapeutics (TARA) in Q1 2018, closing a stake of 283 shares — an estimated $21K sold.

Kornitzer Capital Management first reported a position in TARA in Q4 2014 and held it in 13 quarters. The position peaked at $268K in Q2 2015. 30 funds tracked by Wall St. Rank hold TARA as of Q1 2018.

Kornitzer Capital Management reported no remaining Protara Therapeutics position as of Q1 2018 after selling out during the quarter.
Kornitzer Capital Management sold 283 Protara Therapeutics shares in Q1 2018, an estimated $21K.
Kornitzer Capital Management first reported a position in Protara Therapeutics in Q4 2014 and held it in 13 quarters.
Kornitzer Capital Management's Protara Therapeutics position peaked at $268K in Q2 2015.
30 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2018.

Based on Kornitzer Capital Management's 13F filing for Q1 2018, filed 30 Apr 2018.